P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1d
12 d’oct., 9:49:20 GMT+8 · SGD
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a P8A...
Capitalització borsària
32,37 M
Volum mitjà
1,32 k
Volum
0,00
Alt 52 setmanes
0,26 SGD
Baix 52 setmanes
0,10 SGD
BPA
-0,04 SGD
Accions en circulació
267,53 M
Nombre d'empleats
111
Capitalització borsària
32,37 M
Volum mitjà
1,32 k
Volum
0,00
Alt 52 setmanes
0,26 SGD
Baix 52 setmanes
0,10 SGD
BPA
-0,04 SGD
Accions en circulació
267,53 M
Nombre d'empleats
111
Notícies
De fonts web i partners de notícies
Stocktwits
·
fa 1 hora
S&P 500, Nasdaq See Worst Day In Over Two Months As Chipmaker Rout Deepens, CPI Data Comes In Hot — AAPL, SPCX, DRAM, SOXX In Focus
Simply Wall Street
·
fa 32 minuts
Top 3 Undervalued Stocks To Watch In October 2026
Yahoo Finance
·
fa 1 hora
Invesco QQQ Doesn't Own a Single Bank, and That's Not the Only Thing the Nasdaq-100 Leaves Out
Bloomberg.com
·
fa 4 hores
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
Perfil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Sobre Cordlife Group Ltd
Conseller delegatYiu Pang Fai
Empleats111
Fundació2 de maig 2001
Seu principal-
Sector-
Lloc webcordlife.com